Last reviewed · How we verify
Phase 1b: LB-LR1109 and Atezolizumab — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Phase 1b: LB-LR1109 and Atezolizumab (Phase 1b: LB-LR1109 and Atezolizumab) — LG Chem.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Phase 1b: LB-LR1109 and Atezolizumab TARGET | Phase 1b: LB-LR1109 and Atezolizumab | LG Chem | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Phase 1b: LB-LR1109 and Atezolizumab CI watch — RSS
- Phase 1b: LB-LR1109 and Atezolizumab CI watch — Atom
- Phase 1b: LB-LR1109 and Atezolizumab CI watch — JSON
- Phase 1b: LB-LR1109 and Atezolizumab alone — RSS
Cite this brief
Drug Landscape (2026). Phase 1b: LB-LR1109 and Atezolizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/phase-1b-lb-lr1109-and-atezolizumab. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab